HRP20200456T1 - Farmaceutski pripravak - Google Patents
Farmaceutski pripravak Download PDFInfo
- Publication number
- HRP20200456T1 HRP20200456T1 HRP20200456TT HRP20200456T HRP20200456T1 HR P20200456 T1 HRP20200456 T1 HR P20200456T1 HR P20200456T T HRP20200456T T HR P20200456TT HR P20200456 T HRP20200456 T HR P20200456T HR P20200456 T1 HRP20200456 T1 HR P20200456T1
- Authority
- HR
- Croatia
- Prior art keywords
- isotope
- solution
- binding agent
- selective binding
- alpha
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims 2
- 239000000243 solution Substances 0.000 claims 25
- 239000011230 binding agent Substances 0.000 claims 23
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 claims 16
- 229910052776 Thorium Inorganic materials 0.000 claims 16
- 238000000034 method Methods 0.000 claims 15
- 229910052705 radium Inorganic materials 0.000 claims 9
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 claims 9
- 239000003446 ligand Substances 0.000 claims 8
- 230000009870 specific binding Effects 0.000 claims 5
- 239000003729 cation exchange resin Substances 0.000 claims 4
- 229940023913 cation exchange resins Drugs 0.000 claims 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 239000012528 membrane Substances 0.000 claims 3
- 239000000919 ceramic Substances 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 125000003473 lipid group Chemical group 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000011324 bead Substances 0.000 claims 1
- 230000009918 complex formation Effects 0.000 claims 1
- 238000010668 complexation reaction Methods 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000012508 resin bead Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000011146 sterile filtration Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Saccharide Compounds (AREA)
- Extraction Or Liquid Replacement (AREA)
Claims (24)
1. Postupak za generiranje pročišćene otopine najmanje jednog alfa-emitirajućeg izotopa torija, navedeni postupak obuhvaća dovođenje u kontakt otopine koja sadrži navedeni najmanje jedan kompleks alfa-emitirajućeg izotopa torija i najmanje jedan izotop radija s najmanje jednim selektivnim vezivnim sredstvom za navedeni izotop radija i zatim izdvajanje navedene otopine najmanje jednog kompleksa alfa-emitirajućeg izotopa torija iz navedenog najmanje jednog selektivnog vezivnog sredstva, pri čemu je selektivno vezivno sredstvo odabrano iz skupine koja sadrži kationske izmjenjivačke smole i hidroksiapatit.
2. Postupak prema patentnom zahtjevu 1 naznačen time što je navedeni alfa-emitirajući izotop torija u obliku kompleksa s ligandom, pri čemu je navedeni ligand konjugiran sa specifičnom veznom skupinom kao što je protutijelo.
3. Postupak prema bilo kojem od prethodnih zahtjeva naznačen time što je navedeno selektivno vezivno sredstvo u obliku, ili je pričvršćeno na, čvrstu podlogu ili gel podlogu.
4. Postupak prema patentnom zahtjevu 3 naznačen time što je navedena čvrsta ili gel podloga u obliku, ili pričvršćena na, najmanje jednu odabranu od membrana, zrnaca smole, zrnaca gela, samo spajajućih lipidnih struktura (npr. liposomi), mikročestica, nanočestica, prašaka, kristala, keramika i polimernih struktura.
5. Postupak prema bilo kojem od prethodnih zahtjeva naznačen time što se navedena otopina dovodi u kontakt s navedenim selektivnim vezivnim sredstvom putem strujanja navedene otopine kroz ili pored navedenog selektivnog vezivnog sredstva ili kroz ili pored podloge na kojoj je imobilizirano navedeno selektivno vezivno sredstvo.
6. Postupak prema patentnom zahtjevu 5 naznačen time što je navedeno dovođenje u kontakt putem filtracije u kojem navedena otopina struji kroz ili pored navedenog selektivnog vezivnog sredstva ili kroz ili pored podloge na kojoj je imobilizirano navedeno selektivno vezivno sredstvo.
7. Postupak prema patentnom zahtjevu 6 naznačen time što navedena filtracija nadalje uključuje strujanje navedene otopine kroz sterilnu filtracijsku membranu.
8. Postupak prema bilo kojem od prethodnih zahtjeva naznačen time što navedeno dovođenje u kontakt provodi tijekom perioda od manje od 30 minuta, kao što je manje od 10 minuta, npr. manje od 5 minuta ili manje od 1 minute (npr. ne više od 30 sekundi).
9. Postupak prema bilo kojem od patentnih zahtjeva 1 do 4 naznačen time što se navedena otopina dovodi u kontakt s navedenim selektivnim vezivnim sredstvom dodavanjem navedenog selektivnog vezivnog sredstva i navedene otopine u spremnik (npr. zabrtvljenu ili djelomično zabrtvljenu posudu).
10. Postupak prema patentnom zahtjevu 9 naznačen time što se navedeno dovođenje u kontakt provodi tijekom 30 minuta ili dulje, (npr. 1 sat ili dulje, kao što je 1 dan ili dulje)
11. Komplet za dobivanje farmaceutskog pripravka najmanje jednog kompleksa alfa-emitirajućeg izotopa torija, te navedeni komplet sadrži:
i) otopinu navedenog najmanje jednog alfa-emitirajućeg izotopa torija i najmanje jednog izotopa radija;
ii) najmanje jedan ligand;
iii) specifičnu veznu skupinu;
iv) najmanje jedno selektivno vezivno sredstvo za navedeni najmanje jedan izotop radija.
pri čemu je navedeni alfa-emitirajući izotop torija kompleksiran ili se može kompleksirati s navedenim ligandom koji je konjugiran ili se može konjugirati na navedenu specifičnu veznu skupinu i selektivno vezivno sredstvo je odabrano iz skupine koja sadrži kationske izmjenjivačke smole i hidroksiapatit.
12. Komplet prema patentnom zahtjevu 11 naznačen time što je navedena otopina navedenog najmanje jednog alfa-emitirajućeg izotopa torija i najmanje jednog izotopa radija prisutna u prvom spremniku (npr. bočici, štrcaljki itd.) i navedeni ligand konjugiran na navedenu specifičnom veznu skupinu prisutan je u drugom spremniku.
13. Komplet prema patentnom zahtjevu 11 ili zahtjevu 12 naznačen time što je navedeno selektivno vezivno sredstvo prisutno u obliku najmanje jednog filtra, kao što je filtar štrcaljke, kroz koji navedena otopina alfa-emitirajućeg izotopa torija može proći nakon kompleksiranja s navedenim ligandom i izborno nakon konjugacije s navedenom specifičnom veznom skupinom.
14. Komplet prema patentnom zahtjevu 11 ili zahtjevu 12 naznačen time što je navedeno selektivno vezivno sredstvo prisutno u obliku ili je pričvršćeno na najmanje jednu čvrstu ili gel podlogu.
15. Komplet prema patentnom zahtjevu 14 naznačen time što je navedeno selektivno vezivno sredstvo prisutno u navedenom prvom spremniku.
16. Komplet prema bilo kojem od patentnih zahtjeva 11 do 15 naznačen time što je navedeno selektivno vezivno sredstvo izvedeno tako da se odvaja iz navedene otopine postupkom primjene navedene otopine.
17. Komplet prema patentnom zahtjevu 16 naznačen time što je navedena kruta ili gel podloga najmanje jedna koja je odabrana od membrana, zrnaca smole, zrnaca gela, samo spajajućih lipidnih struktura (npr. liposomi), mikročestica, nanočestica, prašaka, kristala i polimernih struktura.
18. Komplet prema bilo kojem od patentnih zahtjeva 11 do 17 naznačen time što dodatno sadrži filter i/ili uređaj za unošenje.
19. Komplet prema bilo kojem od patentnih zahtjeva 11 do 18 naznačen time što sadrži filter veličine pora od ne više od 0,22 µm.
20. Uređaj za administraciju koji sadrži otopinu najmanje jednog kompleksa alfa-emitirajućeg izotopa torija i najmanje jednog izotopa radija, pri čemu navedeni uređaj nadalje sadrži filter koji sadrži najmanje jedno selektivno vezivno sredstvo za navedeni izotop radija, pri čemu je selektivno vezivno sredstvo odabrano iz skupine koja sadrži kationske izmjenjivačke smole i keramički hidroksiapatit.
21. Uređaj prema patentnom zahtjevu 20 naznačen time što je u obliku štrcaljke za jednokratnu upotrebu i filtera štrcaljke.
22. Komplet prema bilo kojem od patentnih zahtjeva 11 do 19 naznačen time što sadrži uređaj za administraciju koji sadrži otopinu najmanje jednog kompleksiranog alfa- emitirajućeg radionuklida i najmanje jednog nuklida kćeri, pri čemu navedeni komplet dodatno sadrži selektivno vezivno sredstvo za navedeni nuklid kćeri u obliku filtra.
23. Postupak za stvaranje otopine za injekciju kompleksa izotopa torija naznačen time što sadrži korake:
a) kombiniranje prve otopine koja sadrži otopljenu sol alfa-emitirajućeg izotopa torija i najmanje jednog izotopa radija s drugom otopinom koja sadrži najmanje jedan ligand konjugiran s najmanje jednim ciljajućim dijelom;
b) inkubiranje kombiniranih otopina na prikladnoj temperaturi (npr. 0°C do 50°C, poželjno 20°C do 40°C) tijekom perioda kako bi se omogućilo nastajanje kompleksa između navedenog liganda i navedenog alfa-emitirajućeg izotopa torija pri čemu nastaje otopina najmanje jednog kompleksa alfa-emitirajućeg izotopa torija;
c) dovođenje u kontakt navedene otopine najmanje jednog kompleksa alfa-emitirajućeg izotopa torija s najmanje jednim selektivnim vezivnim sredstvom za navedeni najmanje jedan izotop radija, pri čemu je selektivno vezivno sredstvo odabrano iz skupine koja sadrži kationske izmjenjivačke smole i hidroksiapatit;
d) odvajanje navedene otopine najmanje jednog kompleksa alfa-emitirajućeg izotopa torija od navedenog najmanje jednog selektivnog vezivnog sredstva.
24. Postupak za stvaranje otopine za injekciju prema patentnom zahtjevu 23 naznačen time što koraci c) i d) obuhvaćaju postupak za generiranje pročišćene otopine u skladu s bilo kojim od zahtjeva 1 do 10.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1310028.4A GB201310028D0 (en) | 2013-06-05 | 2013-06-05 | Pharmaceutical preparation |
| EP14728571.2A EP3003401B1 (en) | 2013-06-05 | 2014-06-05 | Pharmaceutical preparation |
| PCT/EP2014/061743 WO2014195423A1 (en) | 2013-06-05 | 2014-06-05 | Pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200456T1 true HRP20200456T1 (hr) | 2020-06-26 |
Family
ID=48805787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200456TT HRP20200456T1 (hr) | 2013-06-05 | 2020-03-19 | Farmaceutski pripravak |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US20160114063A1 (hr) |
| EP (1) | EP3003401B1 (hr) |
| JP (1) | JP6580559B2 (hr) |
| KR (1) | KR102321763B1 (hr) |
| CN (1) | CN105592863B (hr) |
| AP (1) | AP2015008894A0 (hr) |
| AU (1) | AU2014276885B2 (hr) |
| BR (1) | BR112015030298A2 (hr) |
| CA (1) | CA2914278C (hr) |
| CL (1) | CL2015003554A1 (hr) |
| CR (1) | CR20150642A (hr) |
| CU (1) | CU24535B1 (hr) |
| DK (1) | DK3003401T3 (hr) |
| DO (1) | DOP2015000294A (hr) |
| EA (1) | EA201501174A1 (hr) |
| ES (1) | ES2782624T3 (hr) |
| GB (1) | GB201310028D0 (hr) |
| HR (1) | HRP20200456T1 (hr) |
| IL (1) | IL242704B (hr) |
| LT (1) | LT3003401T (hr) |
| MA (1) | MA38650B1 (hr) |
| MX (1) | MX366028B (hr) |
| MY (1) | MY180717A (hr) |
| NI (1) | NI201500173A (hr) |
| PE (1) | PE20160215A1 (hr) |
| PH (1) | PH12015502715B1 (hr) |
| PL (1) | PL3003401T3 (hr) |
| PT (1) | PT3003401T (hr) |
| RS (1) | RS60091B1 (hr) |
| SA (1) | SA515370233B1 (hr) |
| SG (1) | SG11201509856RA (hr) |
| SI (1) | SI3003401T1 (hr) |
| TN (1) | TN2015000527A1 (hr) |
| UA (1) | UA120352C2 (hr) |
| WO (1) | WO2014195423A1 (hr) |
| ZA (1) | ZA201600027B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201600158D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Purification method |
| GB201600161D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope purification method |
| CA3208778A1 (en) | 2021-01-22 | 2022-07-28 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
| NO347755B1 (en) * | 2021-10-21 | 2024-03-18 | Blue Wave Therapeutics Gmbh | Peptide-coupled alginate gels comprising radionuclides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5749042A (en) * | 1997-01-28 | 1998-05-05 | Battelle Memorial Institute | Bismuth generator method |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| US8481694B2 (en) * | 2009-04-29 | 2013-07-09 | Bio-Rad Laboratories, Inc. | Purification of immunoconjugates |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201105298D0 (en) * | 2011-03-29 | 2011-05-11 | Algeta Asa | Pharmaceutical preparation |
-
2013
- 2013-06-05 GB GBGB1310028.4A patent/GB201310028D0/en not_active Ceased
-
2014
- 2014-06-05 TN TN2015000527A patent/TN2015000527A1/en unknown
- 2014-06-05 AP AP2015008894A patent/AP2015008894A0/xx unknown
- 2014-06-05 CA CA2914278A patent/CA2914278C/en active Active
- 2014-06-05 EA EA201501174A patent/EA201501174A1/ru unknown
- 2014-06-05 WO PCT/EP2014/061743 patent/WO2014195423A1/en active Application Filing
- 2014-06-05 ES ES14728571T patent/ES2782624T3/es active Active
- 2014-06-05 PL PL14728571T patent/PL3003401T3/pl unknown
- 2014-06-05 MA MA38650A patent/MA38650B1/fr unknown
- 2014-06-05 US US14/896,424 patent/US20160114063A1/en not_active Abandoned
- 2014-06-05 RS RS20200349A patent/RS60091B1/sr unknown
- 2014-06-05 PE PE2015002566A patent/PE20160215A1/es unknown
- 2014-06-05 JP JP2016517608A patent/JP6580559B2/ja not_active Expired - Fee Related
- 2014-06-05 PT PT147285712T patent/PT3003401T/pt unknown
- 2014-06-05 UA UAA201512920A patent/UA120352C2/uk unknown
- 2014-06-05 MY MYPI2015704399A patent/MY180717A/en unknown
- 2014-06-05 KR KR1020157036893A patent/KR102321763B1/ko active IP Right Grant
- 2014-06-05 CN CN201480044621.8A patent/CN105592863B/zh active Active
- 2014-06-05 SG SG11201509856RA patent/SG11201509856RA/en unknown
- 2014-06-05 SI SI201431535T patent/SI3003401T1/sl unknown
- 2014-06-05 AU AU2014276885A patent/AU2014276885B2/en active Active
- 2014-06-05 CU CU2015000174A patent/CU24535B1/es unknown
- 2014-06-05 LT LTEP14728571.2T patent/LT3003401T/lt unknown
- 2014-06-05 MX MX2015016726A patent/MX366028B/es active IP Right Grant
- 2014-06-05 DK DK14728571.2T patent/DK3003401T3/da active
- 2014-06-05 EP EP14728571.2A patent/EP3003401B1/en active Active
- 2014-06-05 BR BR112015030298A patent/BR112015030298A2/pt active Search and Examination
-
2015
- 2015-11-22 IL IL242704A patent/IL242704B/en active IP Right Grant
- 2015-12-03 SA SA515370233A patent/SA515370233B1/ar unknown
- 2015-12-04 CR CR20150642A patent/CR20150642A/es unknown
- 2015-12-04 PH PH12015502715A patent/PH12015502715B1/en unknown
- 2015-12-04 NI NI201500173A patent/NI201500173A/es unknown
- 2015-12-04 DO DO2015000294A patent/DOP2015000294A/es unknown
- 2015-12-04 CL CL2015003554A patent/CL2015003554A1/es unknown
-
2016
- 2016-01-04 ZA ZA2016/00027A patent/ZA201600027B/en unknown
-
2020
- 2020-03-19 HR HRP20200456TT patent/HRP20200456T1/hr unknown
-
2021
- 2021-05-04 US US17/307,857 patent/US20220023449A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200456T1 (hr) | Farmaceutski pripravak | |
| Jafarieh et al. | Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting | |
| Breadmore et al. | Recent advances in enhancing the sensitivity of electrophoresis and electrochromatography in capillaries and microchips (2014–2016) | |
| Apostolidis et al. | Production of Ac-225 from Th-229 for targeted α therapy | |
| González et al. | Radioactive labeling of milk-derived exosomes with 99mTc and in vivo tracking by SPECT imaging | |
| Nam et al. | Water and oil insoluble PEGDA-based microcapsule: biocompatible and multicomponent encapsulation | |
| Parfejevs et al. | Adult stem cell-derived extracellular vesicles in cancer treatment: opportunities and challenges | |
| JP2013503831A5 (hr) | ||
| Wang et al. | Controlled fabrication of functional capsules based on the synergistic interaction between polyphenols and MOFs under weak basic condition | |
| HRP20170625T1 (hr) | Postupak za proizvodnju farmaceutskog pripravka koji sadrži glatiramer acetat | |
| ATE40292T1 (de) | Verfahren zur herstellung von unilamellaren liposomen von grobem diameter, ihre pharmazeutische anwendung fuer die verkapselung von aktivem prinzip fuer die verzoegerte wirkstoffabgabe und vorrichtung hierfuer. | |
| HRP20171272T4 (hr) | Sustavi i metode za povećanje prinosa proteina iz postupka rekombinatne proizvodnje | |
| Lahiri et al. | Radio-green chemistry and nature resourced radiochemistry | |
| CN103648534A (zh) | 药物制剂 | |
| Kim et al. | A microfluidic manifold with a single pump system to generate highly mono-disperse alginate beads for cell encapsulation | |
| Oshchepkova et al. | Extracellular vesicles for therapeutic nucleic acid delivery: loading strategies and challenges | |
| Grieve et al. | The synthesis of a bis (Thiosemicarbazone) macrocyclic ligand and the Mn (II), Co (II), Zn (II) and 68Ga (III) complexes | |
| Toman et al. | Effect of chlorhexidine on bond strength between glass-fiber post and root canal dentine after six month of water storage. | |
| Galán et al. | Ordered co-encapsulation of chloride with polar neutral guests in a tetraurea calix [4] pyrrole dimeric capsule | |
| Luo et al. | A surface multiple imprinting layers membrane with well-oriented recognition sites for selective separation of chlorogenic acid from Ficus carica L. | |
| Park et al. | Novel and efficient preparation of precursor [188Re (OH2) 3 (CO) 3]+ for the labeling of biomolecules | |
| HRP20220271T1 (hr) | Čvrsti oralni pripravci sa sporim otpuštanjem | |
| CN101486734A (zh) | 99Tcm(CO)3环丙沙星氨荒酸盐配合物及制备方法和应用 | |
| Saha et al. | Bioengineering of extracellular vesicles: exosome-based next-generation therapeutic strategy in cancer | |
| CN101289466B (zh) | 99TcmN核标记环丙沙星氨荒酸盐配合物及制备方法和应用 |